OUTLOOK THERAPEUTICS, INC. Stock Nasdaq
Stocks
US68235M1053
Biotechnology & Medical Research
| Market Cap | 165M 143M 135M 123M 230M 15.81B 231M 1.61B 623M 8.02B 619M 605M 25.56B | P/E 2026 * |
-1.17x | P/E 2027 * | -3.12x |
|---|---|---|---|---|---|
| Enterprise Value | 165M 143M 135M 123M 230M 15.81B 231M 1.61B 623M 8.02B 619M 605M 25.56B | EV / Sales 2026 * |
241x | EV / Sales 2027 * | 3.74x |
| Free-Float |
86.07% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OUTLOOK THERAPEUTICS, INC.
| 1 day | -0.09% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Jahr
CEO | Chief Executive Officer | 54 | 2025-06-30 |
Kevin Lundquist
DFI | Director of Finance/CFO | 59 | 2026-08-31 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 2023-01-18 |
| Director | Title | Age | Since |
|---|---|---|---|
Kurt Hilzinger
BRD | Director/Board Member | 65 | 2015-12-10 |
| Chairman | 41 | 2025-01-30 | |
Yazan Haddadin
BRD | Director/Board Member | 50 | 2017-10-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | +11.48% | - | - | 164M | |
| +0.22% | +0.07% | -1.90% | +8.24% | 45.81B | |
| -0.32% | +4.61% | +43.90% | +26.98% | 44.39B | |
| -4.36% | -5.66% | +338.30% | +516.88% | 43.91B | |
| +0.46% | -0.83% | +6.38% | +73.76% | 39.4B | |
| -0.17% | -3.22% | +10.29% | +38.69% | 31.26B | |
| -0.65% | +5.14% | +25.61% | +120.17% | 17.32B | |
| +3.30% | -5.03% | - | - | 15.75B | |
| +1.66% | +5.30% | +19.25% | +34.93% | 14.73B | |
| +0.86% | +9.05% | +0.47% | -33.54% | 13.31B | |
| Average | +0.09% | +0.38% | +55.29% | +98.26% | 29.54B | |
| Weighted average by Cap. | -0.40% | -0.28% | +72.06% | +122.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 683K 592K 559K 508K 951K 65.49M 957K 6.68M 2.58M 33.22M 2.56M 2.51M 106M | 44.07M 38.19M 36.1M 32.77M 61.42M 4.23B 61.79M 431M 167M 2.14B 166M 162M 6.84B |
| Net income | -65.1M -56.42M -53.32M -48.41M -90.73M -6.25B -91.27M -637M -246M -3.17B -245M -239M -10.1B | -44.43M -38.51M -36.39M -33.04M -61.93M -4.26B -62.3M -434M -168M -2.16B -167M -163M -6.89B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
